Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap ...

Pliant stock crashes 89% in three months following setbacks in the mid-stage study of its lead candidate, bexotegrast, for idiopathic pulmonary fibrosis.

A fresh topic of intrigue, among girlfriends enmeshed in the dating scene. Where are the questions from the men? Where is ...

Impressed with the success of Israel’s ‘Iron Dome’ missile defense against a attack by Iranian missiles and drones, President ...

Michael LaRosa was Jill Biden's press secretary for the first 18 months of Joe Biden's presidency, and in recent weeks he's ...

BMW M340i has been updated with Adaptive M suspension, a new colour option and subtle updates to the interior. Tap here to ...

One just has to scroll through Instagram reels to realise how casual misogyny camouflaged as content is consumed daily by lakhs of people in India. Since 2015, The Wire has fearlessly delivered ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Assembly Biosciences (ASMB – Research Report) today. The company’s shares closed ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

New York, New York-- (Newsfile Corp. - March 21, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Pliant Therapeutics, Inc. ("Pliant" or ...